Promis Neurosciences Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs such as Medicare and Medicaid for products. Its market segments include federal healthcare programs, private third-party payors, covered healthcare providers, health plans, healthcare clearinghouses, business associates, independent contractors, and agents of covered entities. Healthcare practitioners served include physicians, dentists, optometrists, podiatrists, chiropractors, and teaching hospitals. Additionally, the company works with manufacturers of drugs, medical devices, biologicals, and medical supplies that receive payment under Medicare, Medicaid, or the State Children’s Health Insurance Program.
In a notable development within the realm of Alzheimer’s disease research, ProMIS Neurosciences has shared pivotal topline results from its Phase 1a clinical trial, involving its innovative therapeutic candidate, PMN310. Conducted in healthy volunteers, the trial sought to assess the agent s safety, tolerability, and pharmacokinetics, paving the way for future investigations in Alzheimer’s patients.The trial s outcomes have been promising, revealing a commendable safety profile and a high level of tolerability across four ascending dose levels. This safety assessment provides a critical foundation for ProMIS Neurosciences, as successful tolerability and safety are paramount in the development of therapie...
Promis Neurosciences Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs such as Medicare and Medicaid for products. Its market segments include federal healthcare programs, private third-party payors, covered healthcare providers, health plans, healthcare clearinghouses, business associates, independent contractors, and agents of covered entities. Healthcare practitioners served include physicians, dentists, optometrists, podiatrists, chiropractors, and teaching hospitals. Additionally, the company works with manufacturers of drugs, medical devices, biologicals, and medical supplies that receive payment under Medicare, Medicaid, or the State Children’s Health Insurance Program.
Sources:
Promis Neurosciences inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Promis Neurosciences inc’s corporate clients.
For your research, we’ve provided 9 tables on Promis Neurosciences inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
